Author/Editor		Kržišnik-Zorman, Simona
Title		Zgodnja uporaba protiteles proti trombocitnim receptorjem GP IIb/IIIa pri zdravljenju akutnega miokardnega infarkta s koronarno angioplastiko
Type		monografija
Place		Ljubljana
Publisher		Medicinska fakulteta
Publication year		2003
Volume		str. 42
Language		slo
Abstract		We investigated potential benefits of abciximab pretreatment in patients with ST-elevation myocardial infarction undergoing primary angioplasty. 163 patients who received acetylsalicylic acid and heparin (70 units/kg) on admission to emergency departement were randomized to abciximab immediately on admission (A), abciximab immediately before angioplasty (B) and no abciximab (C). Following 10 to 105 minutes of pretreatment with abciximab in group A 32% of patients had TIMI 2/3 epicardial blood flow in infarct related artery. This was significantly more than in groups B (12%) and C (18%) (p=0,04). The angiographic success of primary angioplasty, which restored TIMI 3 flow in ecess of 90%, was comparable between the groups. Following angioplasty, STelevatio decreased for 73% in group A which was significantly more than in groups B (52%) and C (50%) (p=0,008). The incidence of thrombocitopenia and bleeding was not significantly increased in abciximab group. Potential benefits of abciximab as an adjunct to primary angioplasty in ST-elevation myocardial infarction appear to be mainly related to early preatreatment.
Descriptors		MYOCARDIAL INFARCTION ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX CORONARY ANGIOGRAPHY ELECTROCARDIOGRAPHY INTENSIVE CARE UNITS HEPARIN ASPIRIN TREATMENT OUTCOME